Photo of Lynette M. Sholl,  MD

Lynette M. Sholl, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-5985
Fax: (617) 277-9015


lmsholl@partners.org

Lynette M. Sholl, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Associate Pathologist, Pathology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research focuses on identifying pathologic, immunohistochemical, and genetic markers that will improve the classification of lung cancer, provide predictive information regarding therapy, and provide more precise prognostic information. With the advent of high throughput next generation sequencing technologies, I am engaged in translation of novel observations surrounding tumor biology into clinical diagnostics and have a special interest in understanding the genomic modifiers of tumor behavior, morphology, and response to treatment.

Publications

Powered by Harvard Catalyst
  • Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Janne PA. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS mutant lung adenocarcinoma. Clin Cancer Res 2015. PubMed
  • Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ, . Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience. J Thorac Oncol 2015. PubMed
  • Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, Sholl LM, Hahn WC, Meyerson M, Lindeman NI, Van Hummelen P, MacConaill LE. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res 2015; 43:e19. PubMed
  • Sholl LM. Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis. Semin Diagn Pathol 2015. PubMed
  • Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod Pathol 2015. PubMed
  • Hwang DH, Sun H, Rodig SJ, Hornick JL, Sholl LM. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Histopathology 2015. PubMed
  • Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities. Acad Radiol 2014; 21:733-42. PubMed
  • Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. J Thorac Oncol 2014; 9:631-8. PubMed
  • Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol 2014; 202:471-8. PubMed
  • Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris DX, Foulis P, Lee G, Neal JW, Nowak JA, Yu PP, . Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Arch Pathol Lab Med 2014; 138:171-4. PubMed
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 2013. PubMed
  • Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol 2013; 8:1434-7. PubMed
  • Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013; 37:1441-9. PubMed
  • Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013; 19:4532-40. PubMed
  • Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013; 63:187-93. PubMed
  • Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM. Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. Arch Pathol Lab Med 2013. PubMed
  • Howitt BE, Jia Y, Sholl LM, Barletta J. Molecular Alterations in Partially-Encapsulated/Well-Circumscribed Follicular Variant of Papillary Thyroid Carcinoma. Thyroid 2013. PubMed
  • Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013; 8:322-8. PubMed
  • Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Lüer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. Clin Cancer Res 2012; 18:5773-5779. PubMed
  • Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36:1222-7. PubMed
  • Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging 2012; 12:225-35. PubMed
  • Sholl LM, Longtine J. Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloproliferative neoplasms. Curr Protoc Hum Genet 2010; Chapter 10:Unit 10.4. PubMed
  • Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010; 34:1193-8. PubMed
  • Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis. Am J Pathol 2010; 177:415-23. PubMed
  • Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010; 133:922-34. PubMed
  • Sholl LM, Longtine J. Molecular analysis of genetic markers for non-Hodgkin lymphomas. Curr Protoc Hum Genet 2010; Chapter 10:Unit 10.14.1-25. PubMed
  • Sholl LM, Long KB, Hornick JL. Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas. Appl Immunohistochem Mol Morphol 2009; 18:55-61. PubMed
  • Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009; 69:8341-8. PubMed
  • Yu J,Kane S,Wu J,Benedettini E,Li D,Reeves C,Innocenti G,Wetzel R,Crosby K,Becker A,Ferrante M,Cheung WC,Hong X,Chirieac LR,Sholl LM,Haack H,Smith BL,Polakiewicz RD,Tan Y,Gu TL,Loda M,Zhou X,Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009; 15:3023-8. PubMed
  • Wu D, Vu Q, Nguyen A, Stone JR, Stubbs H, Kuhlmann G, Sholl LM, Iafrate AJ. In situ genetic analysis of cellular chimerism. Nat Med 2009; 15:215-9. PubMed
  • Abel GA, Deangelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA. Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol 2008; 83:519-20. PubMed
  • Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007; 20:1028-35. PubMed
  • Sholl LM, Hornick JL, Pinkus JL, Pinkus GS, Padera RF. Immunohistochemical analysis of langerin in langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. Am J Surg Pathol 2007; 31:947-52. PubMed
Hide